Keranova develops instruments and an ultra-fast robotized laser for ophthalmic surgery, initially targeting cataract procedures. The company produced its first clinical prototype in Saint-Etienne leveraging research from two multidisciplinary teams at Jean Monnet University and holds innovations protected by 11 patent families. Its device treated its first patients in December 2018 and is positioned as an alternative to traditional phacoemulsification with the goal of precise, repeatable and automated procedures. Keranova aims to reduce manual intervention through automation and ultimately address refractory problems such as myopia and astigmatism at a later stage. Led by CEO and founder Fabrice Romano, the company intends to use recent funding to accelerate technology development and secure regulatory authorizations to market its solution. The articles report a €24M second financing completed in 2019. Keranova develops instruments for ophthalmic surgery, including a new surgical device that leverages joint multidisciplinary research at Jean Monnet University. The device is designed to substantially reduce manual intervention by increasing automation and precision, improving reproducibility and lowering operator-dependent clinical risk. The company plans to use recent funding to develop prototype surgical equipment and to complete a preclinical study required for filing for clinical trial approval. Keranova was founded in 2015 by Fabrice Romano (CEO) and is led operationally with Sophie Valla as managing director. The company recently completed a Series A round of €4m, providing capital to advance its prototype and regulatory program.

Total raised

$31M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2019